JUISCI | Medical Discovery App | Med Community

🔬Juisci’s AI-powered app automatically curates & summarizes medical content helping you remain up-to-date

🍋#Shotofscience #Scicheck #MedTwitter #MedEd

[JUISCI | Medical Discovery App | Med Community @juisci]

Exercising harder may matter more than exercising more. A recent study published in European Heart Journal, based on data from nearly 500,000 UK Biobank participants, suggests that higher-intensity activity is associated with lower risk of cardiovascular events, atrial fibrillation, type 2 diabetes, inflammatory diseases, metabolic liver disease, respiratory diseases, chronic kidney disease, and dementia, as well as all-cause mortality, regardless of total exercise volume.

These findings suggest that, beyond simply doing more exercise, incorporating higher-intensity efforts may offer meaningful health benefits, provided they are carefully tailored to each individual.

🍋 Want to dive deeper? Explore this study and more by downloading the Juisci app

#ChronicDiseasePrevention #ExerciseMedicine #PhysicalActivity #CardiovascularHealth #HighIntensityExercise #EvidenceBasedMedicine #EuropeanHeartJournal

[JUISCI | Medical Discovery App | Med Community @juisci]

For clinicians, this reinforces a key principle in recurrent miscarriage care: avoid adding empiric treatments without demonstrated benefit. Management should remain focused on appropriate evaluation, clear counselling, and evidence-based supportive care.

👉 Stay ahead of the latest research in medicine by downloading our app (link in comment).

#ClinicalResearch #MedicalEducation #EvidenceBasedMedicine #RecurrentMiscarriage #PregnancyLoss #Hydroxychloroquine

[JUISCI | Medical Discovery App | Med Community @juisci]

💡 Recurrent miscarriage: hydroxychloroquine should not be routine
In a multicentre, randomised, placebo-controlled phase 3 trial, hydroxychloroquine started before conception and continued until 10 weeks’ gestation did not improve livebirth rates versus placebo.

[JUISCI | Medical Discovery App | Med Community @juisci]

Livebirth occurred in 58% of women receiving hydroxychloroquine and 61% receiving placebo, with no significant between-group difference.

[JUISCI | Medical Discovery App | Med Community @juisci]

OpenEvidence just left Europe.
~200,000 European physicians lost access overnight.
European HCPs deserve better than clinical AI that can't, or won't meet basic compliance standards.

#Juisci has been here since 2021. Built under EU jurisdiction.
hashtag #AI Act compliant by design. 40,000 European HCPs, every month. We're not replacing OpenEvidence... yet. But 𝘄𝗲'𝗿𝗲 𝗼𝗻𝗲 𝗼𝗳 𝘁𝗵𝗲 𝗲𝗮𝘀𝗶𝗲𝘀𝘁 𝘄𝗮𝘆𝘀 𝘁𝗼 𝘀𝘁𝗮𝘆 𝗼𝗻 𝘁𝗼𝗽 𝗼𝗳 𝘀𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰 𝗹𝗶𝘁𝗲𝗿𝗮𝘁𝘂𝗿𝗲 𝗶𝗻 𝘆𝗼𝘂𝗿 𝗳𝗶𝗲𝗹𝗱.

→ Try Juisci · https://t.co/vXFXhvTx6Y (free for HCPs)

hashtag#BuiltInEurope hashtag#BuiltToLast hashtag#ClinicalAI hashtag#Juisci hashtag#Science hashtag#IA

[JUISCI | Medical Discovery App | Med Community @juisci]

👉 If you missed the bioMérieux symposium at ESCMID — or just want to revisit it without digging through abstracts — this playlist brings together the key publications and clinical takeaways. Built for ID specialists and clinical microbiologists 👇
https://t.co/yqwV6OBo01

#InfectiousDiseases

[JUISCI | Medical Discovery App | Med Community @juisci]

5,000+ abstracts. 16,000 experts in Munich. One clear reality: science is moving faster than clinicians can keep up with.

[JUISCI | Medical Discovery App | Med Community @juisci]

Here's what that looks like in practice : the playlist related to bioMérieux's symposium on "STRIDES in AMR: Diagnostics driving impact", available in #Juisci App !

[JUISCI | Medical Discovery App | Med Community @juisci]

💡 New insights in gut microbiome and antimicrobial stewardship

This large Swedish population-based study of 14,979 adults demonstrates that oral antibiotic exposure is associated with long-lasting reductions in gut microbial diversity and altered species abundance in a general adult population, persisting up to 8 years after use while underscoring that specific classes drive most of these sustained changes and should factor into long-term prescribing decisions.
Swipe through to explore the key findings and their implications for antibiotic prescribing and gut health.

👉 Want a deeper dive ? Chat with the paper in our app (link in bio)

#ClinicalResearch #MedicalEducation #EvidenceBasedMedicine #Gastroenterology #Microbiome #InfectiousDisease #AntimicrobialStewardship

[JUISCI | Medical Discovery App | Med Community @juisci]

👉 Stay ahead of the latest research in medicine by downloading our app (link in bio).

#ClinicalResearch #MedicalEducation #EvidenceBasedMedicine #Depression #Psychiatry

[JUISCI | Medical Discovery App | Med Community @juisci]

💡 New insights in treatment-resistant depression. One day of treatment. That's all it took. In this phase 2b randomized trial (JAMA Psychiatry, 2026), a single session of inhaled mebufotenin (GH001) led to remission in 57.5% of patients with treatment-resistant depression by day 8, versus 0% with placebo. NNT = 2. Effect size = -2.0, a magnitude rarely seen in psychiatry.

[JUISCI | Medical Discovery App | Med Community @juisci]

Tolerability was reassuring, with no severe adverse events. And among patients in remission at day 8, 87% maintained it at 6 months with only infrequent retreatments.

For a population that has failed at least two antidepressants, these results are hard to ignore.

[JUISCI | Medical Discovery App | Med Community @juisci]

👉 Try it on a real paper : https://t.co/s9QiFmTSS9

[JUISCI | Medical Discovery App | Med Community @juisci]

Scientific papers are often : Too long. Too dense. Hard to use quickly.
That’s exactly why we built this 👇

[JUISCI | Medical Discovery App | Med Community @juisci]

No wasted time. No guesswork.